Experimental dissidence: economies of credibility in drug regulation
In 2004, a former FDA medical officer named David Ross watched news coverage of one of the highest-profile pharmaceutical controversies in recent years: Merck’s withdrawal of Vioxx, its bestselling painkiller, from the global marketplace. At the time, David Ross railed to his wife about the actions...
Hoofdauteur: | |
---|---|
Formaat: | Conference item |
Gepubliceerd in: |
2010
|